Better Delineation of YY1 Related Phenotype and Epigenetic Signatures.

YY1 Related Disorder : Clinical Phenotype, Neuropsychological Profile, Brain MRI Characteristics and Epigenetic Signatures.

YY1 related disorder, also known as Gabriele-de-Vries syndrome, is mainly characterised by developmental delay (DD) and intellectual disability (ID), ranging from mild to severe, and neuroimaging abnormalities.

The aims of this study are first to better delineate the clinical phenotype, as well as the neuropsychological profile, and the brain MRI characteristics; and, second, to study the epigenetic signatures in a cohort of individuals with YY1 intragenic pathogenic variants. This work will conduct to a MD thesis of a clinical resident geneticist in France.

Physician that will participate will fill an Excel sheet regarding the clinical and neuropsychological assessment. The investigators will be also happy to have either CD-ROM or a link to have access to the brain MRI data as well as a DNA sample with a minimum 0.5ug of peripheral blood genomic DNA. The investigators will gather the DNA in Montpellier genetic lab (Dr Mouna BARAT) and send the batch to the Dr Sadikovic' lab.

Between 2019 and 2020, the investigators have already recruited data from individuals with YY1 pathogenic variants from several European and American genetic centres.

Study Overview

• Status: Unknown
• Conditions: YY1 Related Disorder
• Intervention / Treatment: Genetic: Epigenetic signatures

Detailed Description

The investigators aim to better understand and delineate the genetic syndrome YY1 (a.k.a. Gabriele-de-Vries syndrome).

This genetic disorder was described in June 2017 in the American Journal of Human Genetics (PMID 28575647).

Since this first publication of 23 individuals carrying the pathogenic mutation YY1, another individual has been reported in the literature (PMID 30549423).

In addition, the first paper focused on the clinical description as well as the effect of pathogenic YY1 variations in chromatin regulation.

The investigators are seeking to better define the phenotype of individuals with pathogenic variants of YY1, to better understand intellectual functioning as well as the strengths and weaknesses of intellectual functioning by collecting standardized neuropsychological assessments already performed such as WPPSI/WISC and WAIS. For this purpose, the investigators will gather clinical and neuropsychological data already carried out in the context of care.

The investigators also aim to gather the cerebral MRI scans already performed in order to better delimit the cerebral anomalies observed in individuals and if the sequence is adapted, the investigators will perform VBM studies.

Finally, the investigators will attempt to identify an epigenetic signature in this genetic disease. To this end, the investigators will collect genomic DNA from peripheral blood already collected for genetic analysis and send an anonymized batch of samples to our collaborator, Dr. Bekim Sadicovik. Dr. Bekim Sadicovik and his team will compare the epigenetic DNA methylation-type markers with the corresponding sex and age controls. If specific probes are abnormally methylated in YY1 individuals, this will determine a disease-specific epigenetic signature. The investigators will then be able to propose an epigenetic signature for individuals with uncharacterized YY1 variations (class 3, VUS). This method will make it possible to define whether the variation is responsible for the disease or not without going through functional analysis steps that are difficult to implement routinely.

The expected benefits are a better understanding of YY1 disease, keys to neuropsychological rehabilitation, a better understanding of human brain functions, the possibility of proposing an epigenetic signature for people in whom it is not possible to decide whether a variation in the YY1 gene is pathological or not

• Study Type: Observational
• Enrollment (Anticipated): 10

Contacts and Locations

• Study Contact: Name: David GENEVIEVE, MH PD; Phone Number: 33 04 67 33 61 04; Email: d-genevieve@chu-montpellier.fr
• Study Contact Backup: Name: Pauline MONIN, Resident; Email: p-monin@chu-montpellier.fr

Study Locations

• France
  • Montpellier, France, 34295
    • Recruiting
    • UH Montpellier
    • Contact: David GENEVIEVE; Email: d-genevieve@chu-montpellier.fr
    • Sub-Investigator: Bekim SADIKOVIC, DR
    • Contact: Pauline MONIN, Resident; Email: p-monin@chu-montpellier.fr
    • Sub-Investigator: Florian CHERIK, DR

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Individuals with YY1 intragenic pathogenic SNV (Single Nucleotide Variant)

Description

Inclusion criteria:

- YY1 intragenic pathogenic SNV (Single Nucleotide Variant)

Exclusion criteria:

• no pathogenic SNV in YY1
• no consent for the study

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Other

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
YY1; YY1 intragenic pathogenic variant	Genetic: Epigenetic signatures; Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
YY1 related clinical and neuropsychological phenotype phenotype and brain MRI description	YY1 related clinical and neuropsychological phenotype phenotype and brain MRI description	1 day
Evolution of genetic data	Evolution of genetic data	1 day

Collaborators and Investigators

• Sponsor: University Hospital, Montpellier
• Investigators: Principal Investigator: David GENEVIEVE, Department of Medical Genetics

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2020
• Primary Completion (Anticipated): December 1, 2020
• Study Completion (Anticipated): December 1, 2020

Study Registration Dates

• First Submitted: May 6, 2020
• First Submitted That Met QC Criteria: May 6, 2020
• First Posted (Actual): May 11, 2020

Study Record Updates

• Last Update Posted (Actual): May 14, 2020
• Last Update Submitted That Met QC Criteria: May 12, 2020
• Last Verified: May 1, 2020

More Information

Terms related to this study

• Keywords: YY1
• Other Study ID Numbers: RECHMPL20_0272

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided
• IPD Plan Description: NC

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No